<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04837898</url>
  </required_header>
  <id_info>
    <org_study_id>26514</org_study_id>
    <nct_id>NCT04837898</nct_id>
  </id_info>
  <brief_title>Haskap and Exercise Performance</brief_title>
  <official_title>The Influence of Haskap Berry on Exercise Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northumbria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mibelle Group Biochemistry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haskapa Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northumbria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will employ a randomised, double-blind, placebo-controlled, independent groups&#xD;
      experimental design. Submaximal, maximal and 5 km time trial running performance will be&#xD;
      assessed before and after supplementation with haskap berry or a placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will consume haskap berry powder or an isocaloric placebo for 7 days. They will&#xD;
      be required to run on a treadmill before and after supplementation to asses the influence on&#xD;
      the intervention on aerobic performance. Other performance parameters such as blood lactate,&#xD;
      heart rate, ratings of perceived exertion and respiratory variables will also be monitored&#xD;
      throughout the exercise trials.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 12, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>supplement will be pre-weighed by an independent researcher and provided to participants in opaque sachets</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>5km time trial</measure>
    <time_frame>Change from baseline at 7 days</time_frame>
    <description>time to complete 5km running on treadmill (mins)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VÌ‡O2max</measure>
    <time_frame>Change from baseline at 7 days</time_frame>
    <description>maximal oxygen uptake (ml/kg/min)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood lactate</measure>
    <time_frame>Change from baseline at 7 days</time_frame>
    <description>lactate (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rating of perceived exertion</measure>
    <time_frame>Change from baseline at 7 days</time_frame>
    <description>RPE (/20)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Change from baseline at 7 days</time_frame>
    <description>(BPM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Exercise Performance</condition>
  <arm_group>
    <arm_group_label>haskap berry</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A commercially available haskap berry powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Black cherry KoolAid (Kraft Foods, USA) with added maltodextrin to match carbohydrate and calorie content</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Haskapa</intervention_name>
    <description>Haskapa Ltd, Saffron Walden, UK</description>
    <arm_group_label>haskap berry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>isocaloric to the haskap powder</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy non-smoking males&#xD;
&#xD;
          -  completed a 5 km run (in less than 25 minutes) within the 6 weeks prior to the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  females&#xD;
&#xD;
          -  allergies to fruit or dairy, currently taking any nutritional supplements (e.g.&#xD;
             vitamins, antioxidant, herbal or sports enhancing supplements) or medication that&#xD;
             might affect the study outcome&#xD;
&#xD;
          -  history of gastrointestinal, renal or cardiovascular disease&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Glyn Howatson, PhD</last_name>
    <phone>+44 (0)191 227 3575</phone>
    <email>glyn.howatson@northumbria.ac.uk</email>
  </overall_contact>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>berry</keyword>
  <keyword>running</keyword>
  <keyword>time trial</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

